Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities?

被引：11
|
作者：
Chiang, Kelly [1 ]
Davies, Clare C. [1 ]
机构：
[1] Univ Birmingham, Coll Med & Dent Sci, Inst Canc & Genom Sci, Birmingham, W Midlands, England
来源：
MOLECULAR & CELLULAR ONCOLOGY | 2018年 / 5卷 / 03期
基金：
英国医学研究理事会;
关键词：
PRMT5; breast cancer stem cells; epigenetics; arginine methylation; FOXP1;
D O I：
10.1080/23723556.2018.1441628
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The arginine methyitransferase PRMT5 has been increasingly associated with cancer development. Here we describe our recent findings that PRMT5 is a critical regulator of breast cancer stem cell survival via the epigenetic regulation of FOXP1. Consequently, PRMT5 inhibitors could potentially eradicate cancer stem cells thereby preventing tumour relapse.
引用
收藏
页数：3
相关论文
共 50 条
  • [21] PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer
    Zhe Wang
    Jing Kong
    Ying Wu
    Juliang Zhang
    Ting Wang
    Nanlin Li
    Jing Fan
    Hui Wang
    Jian Zhang
    Rui Ling
    Breast Cancer Research and Treatment, 2018, 168 : 531 - 542
  • [22] PRMT5 inhibitor synergizes with PARP inhibitors in triple-negative breast cancer cells
    Suresh, Samyuktha
    McPherson, Lisa A.
    Ford, James M.
    CANCER RESEARCH, 2024, 84 (06)
  • [23] PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer
    Wang, Zhe
    Kong, Jing
    Wu, Ying
    Zhang, Juliang
    Wang, Ting
    Li, Nanlin
    Fan, Jing
    Wang, Hui
    Zhang, Jian
    Ling, Rui
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (02) : 531 - 542
  • [24] Breast cancer stem cells: treatment resistance and therapeutic opportunities
    Al-Ejeh, Fares
    Smart, Chanel E.
    Morrison, Brian J.
    Chenevix-Trench, Georgia
    Lopez, J. Alejandro
    Lakhani, Sunil R.
    Brown, Michael P.
    Khanna, Kum Kum
    CARCINOGENESIS, 2011, 32 (05) : 650 - 658
  • [25] PRMT5 and the role of symmetrical dimethylarginine in chromatoid bodies of planarian stem cells
    Rouhana, Labib
    Vieira, Ana P.
    Roberts-Galbraith, Rachel H.
    Newmark, Phillip A.
    DEVELOPMENT, 2012, 139 (06): : 1083 - 1094
  • [26] Regulation of a PRMT5/NF-κB Axis by Phosphorylation of PRMT5 at Serine 15 in Colorectal Cancer
    Hartley, Antja-Voy
    Wang, Benlian
    Jiang, Guanglong
    Wei, Han
    Sun, Mengyao
    Prabhu, Lakshmi
    Martin, Matthew
    Safa, Ahmad
    Sun, Steven
    Liu, Yunlong
    Lu, Tao
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (10)
  • [27] PRMT1 loss sensitizes cells to PRMT5 inhibition
    Gao, Guozhen
    Zhang, Liang
    Villarreal, Oscar D.
    He, Wei
    Su, Dan
    Bedford, Ella
    Moh, Phoebe
    Shen, Jianjun
    Shi, Xiaobing
    Bedford, Mark T.
    Xu, Han
    NUCLEIC ACIDS RESEARCH, 2019, 47 (10) : 5038 - 5048
  • [28] PRMT5 Is Upregulated in Activated T Cells and Is a Novel Therapeutic Target for Acute Gvhd
    Ranganathan, Parvathi
    Snyder, Katiri
    Zizter, Nina
    Choe, Hannah K.
    Baiocchi, Robert A.
    Vaddi, Kris
    BLOOD, 2018, 132
  • [29] PRMT5 selective inhibitor enhances therapeutic efficacy of cisplatin in lung adenocarcinoma cells
    Bajbouj, Khuloud
    Ramakrishnan, Rakhee
    Ihmaid, Ahmed M. H.
    Ali, Suhaib Al Haj
    Alalool, Abdulla
    Abdullah, Reem
    Saber-Ayad, Maha
    Hamid, Qutayba
    CANCER RESEARCH, 2019, 79 (13)
  • [30] A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer
    Zhang, KeJing
    Wei, Juan
    Zhang, SheYu
    Fei, Liyan
    Guo, Lu
    Liu, Xueying
    Ji, YiShuai
    Chen, WenJun
    Ciamponi, Felipe E.
    Chen, WeiChang
    Li, MengXi
    Zhai, Jie
    Fu, Ting
    Massirer, Katlin B.
    Yu, Yang
    Lupien, Mathieu
    Wei, Yong
    Arrowsmith, Cheryl. H.
    Wu, Qin
    Tan, WeiHong
    CELL CHEMICAL BIOLOGY, 2024, 31 (11)
12345